Copyright
©The Author(s) 2023.
World J Med Genet. Dec 20, 2023; 11(4): 39-50
Published online Dec 20, 2023. doi: 10.5496/wjmg.v11.i4.39
Published online Dec 20, 2023. doi: 10.5496/wjmg.v11.i4.39
Table 1 Demographics of 100 patients included in the retrospective review of pharmacogenomics result
| Patient characteristics | |
| Sex | (%) |
| Male | 44 |
| Female | 56 |
| Age (yr) | (%) |
| 18-29 | 23 |
| 30-39 | 12 |
| 40-49 | 29 |
| 50-59 | 17 |
| 60-69 | 14 |
| > 70 | 5 |
| Referring specialists | (%) |
| Psychiatrists | 39 |
| Immunologists | 15 |
| General practitioners | 10 |
| Neurologists | 9 |
| Transplant physicians | 8 |
| Clinical pharmacologists | 5 |
| Others1 | 14 |
| Indications for referral | (%) |
| To guide pharmacotherapy | 62 |
| Previous drug reactions | 51 |
| Polypharmacy2 | 5 |
| Pre-emptive testing | 5 |
| Did not specify | 5 |
Table 2 Number of patients (n = 56) taking medications found to have high- and/or moderate-risk drug-gene interaction against the number of such medications, in those whose medication history was available (n = 84), n (%)
| Number of medications with implicated DGI | Number of patients taking medications with high-risk +/- moderate-risk DGI implicated | Number of patients taking medications with moderate-risk DGI implicated only | Number of patients taking medications with an actionable1 DGI |
| 1 | 5 (6) | 20 (24) | 25 (30) |
| 2 | 7 (8) | 11 (13) | 18 (21) |
| 3 | 3 (4) | 7 (8) | 10 (12) |
| 4 | 1 (1) | 0 (0) | 1 (1) |
| 5 | 0 (0) | 1 (1) | 1 (1) |
| 6 | 0 (0) | 0 (0) | 0 (0) |
| 7 | 0 (0) | 0 (0) | 0 (0) |
| 8 | 0 (0) | 0 (0) | 0 (0) |
| 9 | 1 (1) | 0 (0) | 1 (1) |
| 10 | 0 (0) | 0 (0) | 0 (0) |
| Total | 17 (20) | 39 (46) | 56 (66) |
Table 3 Patient and clinician survey respondent demographics, n (%)
| Patient respondents (n = 25) | Clinician respondents (n = 17) | ||
| Sex | Sex | ||
| Male | 9 (36.0) | Male | 11 (64.7) |
| Female | 16 (64.0) | Female | 6 (35.3) |
| Patient age (yr) | Clinician attained medical degree | ||
| 18-29 | 4 (16.0) | Before 1980 | 2 (11.8) |
| 30-39 | 2 (8.0) | 1981-1990 | 2 (11.8) |
| 40-49 | 7 (28.0) | 1991-2000 | 3 (17.6) |
| 50-59 | 6 (24.0) | After 2000 | 10 (58.8) |
| 60-69 | 5 (20.0) | ||
| > 70 | 1 (4.0) | ||
| Patient education level | Clinician specialty | ||
| Did not finish high school | 1 (4.0) | Psychiatry | 5 (29.4) |
| High school | 6 (24.0) | Clinical pharmacology | 3 (17.6) |
| Certificate or diploma | 5 (20.0) | Immunology | 2 (11.8) |
| Bachelor’s degree | 11 (44.0) | Neurology | 2 (11.8) |
| Master’s degree or doctorate | 2 (8.0) | General practitioner | 1 (5.9) |
| Other1 | 7 (41.2) |
- Citation: Moxham R, Tjokrowidjaja A, Devery S, Smyth R, McLean A, Roberts DM, Wu KHC. Clinical utilities and end-user experience of pharmacogenomics: 39 mo of clinical implementation experience in an Australian hospital setting. World J Med Genet 2023; 11(4): 39-50
- URL: https://www.wjgnet.com/2220-3184/full/v11/i4/39.htm
- DOI: https://dx.doi.org/10.5496/wjmg.v11.i4.39
